Authorities: Psychiatrist sent more than 50,000 fraudulent Medicare, Medicaid nursing home claims

Share this article:
A Chicago psychiatrist is accused of submitting $190,000 in false claims to Medicare and Medicaid and receiving kickbacks for prescribing antipsychotics.

Michael J. Reinstein, M.D., also allegedly submitted at least 50,000 claims to Medicare and Medicaid, saying he provided “pharmacologic management” for patients at more than 30 area nursing homes and long-term care facilities, the Department of Justice said Thursday.

“This is the largest civil case alleging prescription medication fraud against an individual ever brought in Chicago,” said Gary S. Shapiro, Acting United States Attorney for the Northern District of Illinois

Clozapine, which is prescribed to treat schizophrenia, is under scrutiny in the case: The DOJ says that at one point Reinstein had 1,000 patients on Clozaril as part of an agreement with Novartis to promote the drug. After that agreement ended in 2003, IVAX Pharmaceuticals, Inc. began paying a $50,000 “consulting fee” to Reinstein in exchange for him prescribing generic clozapine, the lawsuit says. Officials say that the physician then “became the largest prescriber of generic clozapine in the country.”

Share this article:

More in News

Nursing home antipsychotic use has dipped nearly 19% under national effort, latest figures show

Nursing home antipsychotic use has dipped nearly 19% ...

The percent of long-stay nursing home residents receiving antipsychotic medication has decreased 18.8% under a nationwide initiative that started in 2012.

Jimmo succeeds in getting Medicare coverage, two years after landmark case ended

Glenda Jimmo has reached a settlement with the federal government and will finally receive Medicare coverage for claims that were denied in 2007, which led her to file a class-action lawsuit over the so-called "improvement standard."

Breier named new CEO at Kindred

Breier named new CEO at Kindred

Kindred Healthcare announced Thursday that it has chosen a new top executive to lead its push toward creating a mammoth national brand. Benjamin A. Breier, the company's current president and ...